Cardiff Oncology Inc (NASDAQ:CRDF) price on current trading day, rose 2.35% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.61.
A look at the stock’s price movement, the close in the last trading session was $2.55, moving within a range at $2.445 and $2.77. The beta value (5-Year monthly) was 1.734. Turning to its 52-week performance, $6.27 and $2.01 were the 52-week high and 52-week low respectively. Overall, CRDF moved -27.09% over the past month.
Cardiff Oncology Inc’s market cap currently stands at around $173.63 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CRDF is a 50% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend CRDF as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CRDF’s current price about -22.87% and -32.67% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 27.69, while 7-day volatility ratio is 10.81% and 7.66% in the 30-day chart. Further, Cardiff Oncology Inc (CRDF) has a beta value of 1.81, and an average true range (ATR) of 0.28.
If we refocus on Cardiff Oncology Inc (NASDAQ:CRDF), historical trading data shows that trading volumes averaged 1.6 over the past 10 days and 1.12 million over the past 3 months. The company’s latest data on shares outstanding shows there are 66.52 million shares.
The 10.13% of Cardiff Oncology Inc’s shares are in the hands of company insiders while institutional holders own 34.43% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.34 million on 2025-03-14, giving us a short ratio of 11.41. The data shows that as of 2025-03-14 short interest in Cardiff Oncology Inc (CRDF) stood at 2045.0 of shares outstanding, with shares short rising to 10.84 million registered in 2025-02-14. Current price change has pushed the stock -39.86% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRDF stock continues to rise going into the next quarter.
